Ascendis Pharma A/S (ASND) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascendis Pharma A/S has reported a substantial first quarter growth in 2024, with SKYTROFA revenue doubling to €65 million and projections suggesting annual revenues reaching €320-340 million. The company has also successfully launched YORVIPATH in Germany and Austria, and is on track with its TransCon CNP pivotal trial, expecting results by Q4 2024. With reduced operating expenses and a strong pipeline, Ascendis is poised for sustainable growth and aims to reach operating cash flow breakeven by the end of 2024.
For further insights into ASND stock, check out TipRanks’ Stock Analysis page.